These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 37219686)
1. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Rasco DW; Medina T; Corrie P; Pavlick AC; Middleton MR; Lorigan P; Hebert C; Plummer R; Larkin J; Agarwala SS; Daud AI; Qiu J; Bozon V; Kneissl M; Barry E; Olszanski AJ Cancer Chemother Pharmacol; 2023 Jul; 92(1):15-28. PubMed ID: 37219686 [TBL] [Abstract][Full Text] [Related]
2. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration. van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNS; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O BMC Cancer; 2024 Jan; 24(1):147. PubMed ID: 38291372 [TBL] [Abstract][Full Text] [Related]
3. Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Guo C; Chénard-Poirier M; Roda D; de Miguel M; Harris SJ; Candilejo IM; Sriskandarajah P; Xu W; Scaranti M; Constantinidou A; King J; Parmar M; Turner AJ; Carreira S; Riisnaes R; Finneran L; Hall E; Ishikawa Y; Nakai K; Tunariu N; Basu B; Kaiser M; Lopez JS; Minchom A; de Bono JS; Banerji U Lancet Oncol; 2020 Nov; 21(11):1478-1488. PubMed ID: 33128873 [TBL] [Abstract][Full Text] [Related]
4. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139 [TBL] [Abstract][Full Text] [Related]
5. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198 [No Abstract] [Full Text] [Related]
6. A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with Sullivan RJ; Weber J; Patel S; Dummer R; Carlino MS; Tan DSW; Lebbé C; Siena S; Elez E; Wollenberg L; Pickard MD; Sandor V; Ascierto PA Clin Cancer Res; 2020 Oct; 26(19):5102-5112. PubMed ID: 32669376 [TBL] [Abstract][Full Text] [Related]
7. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467 [TBL] [Abstract][Full Text] [Related]
8. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Falchook GS; Lewis KD; Infante JR; Gordon MS; Vogelzang NJ; DeMarini DJ; Sun P; Moy C; Szabo SA; Roadcap LT; Peddareddigari VG; Lebowitz PF; Le NT; Burris HA; Messersmith WA; O'Dwyer PJ; Kim KB; Flaherty K; Bendell JC; Gonzalez R; Kurzrock R; Fecher LA Lancet Oncol; 2012 Aug; 13(8):782-9. PubMed ID: 22805292 [TBL] [Abstract][Full Text] [Related]
9. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Zimmer L; Barlesi F; Martinez-Garcia M; Dieras V; Schellens JH; Spano JP; Middleton MR; Calvo E; Paz-Ares L; Larkin J; Pacey S; Venturi M; Kraeber-Bodéré F; Tessier JJ; Eberhardt WE; Paques M; Guarin E; Meresse V; Soria JC Clin Cancer Res; 2014 Aug; 20(16):4251-61. PubMed ID: 24947927 [TBL] [Abstract][Full Text] [Related]
10. A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Izar B; Sharfman W; Hodi FS; Lawrence D; Flaherty KT; Amaravadi R; Kim KB; Puzanov I; Sosman J; Dummer R; Goldinger SM; Lam L; Kakar S; Tang Z; Krieter O; McDermott DF; Atkins MB Cancer Med; 2017 Aug; 6(8):1904-1914. PubMed ID: 28719152 [TBL] [Abstract][Full Text] [Related]
11. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations. Bardia A; Gounder M; Rodon J; Janku F; Lolkema MP; Stephenson JJ; Bedard PL; Schuler M; Sessa C; LoRusso P; Thomas M; Maacke H; Evans H; Sun Y; Tan DSW Oncologist; 2020 Jan; 25(1):e160-e169. PubMed ID: 31395751 [TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489 [TBL] [Abstract][Full Text] [Related]
13. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Kilburn LB; Khuong-Quang DA; Hansford JR; Landi D; van der Lugt J; Leary SES; Driever PH; Bailey S; Perreault S; McCowage G; Waanders AJ; Ziegler DS; Witt O; Baxter PA; Kang HJ; Hassall TE; Han JW; Hargrave D; Franson AT; Yalon Oren M; Toledano H; Larouche V; Kline C; Abdelbaki MS; Jabado N; Gottardo NG; Gerber NU; Whipple NS; Segal D; Chi SN; Oren L; Tan EEK; Mueller S; Cornelio I; McLeod L; Zhao X; Walter A; Da Costa D; Manley P; Blackman SC; Packer RJ; Nysom K Nat Med; 2024 Jan; 30(1):207-217. PubMed ID: 37978284 [TBL] [Abstract][Full Text] [Related]
14. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. Desai J; Gan H; Barrow C; Jameson M; Atkinson V; Haydon A; Millward M; Begbie S; Brown M; Markman B; Patterson W; Hill A; Horvath L; Nagrial A; Richardson G; Jackson C; Friedlander M; Parente P; Tran B; Wang L; Chen Y; Tang Z; Huang W; Wu J; Zeng D; Luo L; Solomon B J Clin Oncol; 2020 Jul; 38(19):2140-2150. PubMed ID: 32182156 [TBL] [Abstract][Full Text] [Related]
15. Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. Lebbé C; Italiano A; Houédé N; Awada A; Aftimos P; Lesimple T; Dinulescu M; Schellens JHM; Leijen S; Rottey S; Kruse V; Kefford R; Raymond E; Faivre S; Pages C; Gomez-Roca C; Schueler A; Goodstal S; Massimini G; Delord JP Target Oncol; 2021 Jan; 16(1):47-57. PubMed ID: 33211315 [TBL] [Abstract][Full Text] [Related]
16. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Falchook GS; Long GV; Kurzrock R; Kim KB; Arkenau TH; Brown MP; Hamid O; Infante JR; Millward M; Pavlick AC; O'Day SJ; Blackman SC; Curtis CM; Lebowitz P; Ma B; Ouellet D; Kefford RF Lancet; 2012 May; 379(9829):1893-901. PubMed ID: 22608338 [TBL] [Abstract][Full Text] [Related]
17. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968 [TBL] [Abstract][Full Text] [Related]
18. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Rosen LS; LoRusso P; Ma WW; Goldman JW; Weise A; Colevas AD; Adjei A; Yazji S; Shen A; Johnston S; Hsieh HJ; Chan IT; Sikic BI Invest New Drugs; 2016 Oct; 34(5):604-13. PubMed ID: 27424159 [TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study. Tibes R; Borad MJ; Dutcus CE; Reyderman L; Feit K; Eisen A; Verbel DA; Von Hoff DD Br J Cancer; 2018 Jun; 118(12):1580-1585. PubMed ID: 29867224 [TBL] [Abstract][Full Text] [Related]
20. First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations. Wang X; Luo Z; Chen J; Chen Y; Ji D; Fan L; Chen L; Zhao Q; Hu P; Sun P; Jia Z; Guo J; Si L BMC Med; 2023 Jan; 21(1):2. PubMed ID: 36600247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]